Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1070806 in obese subjects with type 2 diabetes mellitus
2012-000126-22Phase 2Completed
- Sponsor
- GSK
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing GSK1070806 IV with Placebo IV (2 arms). Primary endpoints: Change from baseline in fasting plasma glucose and Change from baseline in weighted mean glucose AUC (0–4 hours) post-mixed meal test. Started May 2012; status: completed.
02
Drugs
aletekitug
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on 2012-000126-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000126-22.